Snapshot of Australia's COVID-19 vaccines

Matt Coughlan
·2-min read

AUSTRALIA'S CORONAVIRUS VACCINES

* Pfizer - 20 million doses

Australia has struck a deal for 10 million more doses of Pfizer's drug, which had an efficacy rate of 95 per cent in late-stage trials. It will be the first vaccine rolled out in Australia with elderly and vulnerable people as well as frontline health, border and quarantine workers first in the queue. Last week it was approved for use in Australia. It must be stored at minus 70 degrees, making dry ice "eskies" key to its transportation.

* AstraZeneca - 53.8 million doses

The first of 1.2 million imported doses is expected to arrive in early March with local manufacturing to kick in by the end of next month. CSL will produce 50 million doses in Melbourne during the year. The vaccine has an efficacy rate of 70 per cent although this could vary between 62 and 90 per cent based on age, dose and time between shots. Health chiefs say it is 100 per cent effective at preventing serious illness and death from coronavirus.

* Novavax - 51 million doses

The vaccine had an 89 per cent efficacy rating in a phase three UK trial. It was found to be less effective against the South African strain but still had a rating of around 60 per cent, above the World Health Organisation benchmark. Chief Medical Officer Paul Kelly has said that protein vaccines like Novavax are likely to be the world's long-term option against coronavirus. It is expected to be approved later in the year.

* Covax facility - more than 25 million doses

Australia is one of 188 countries in the global effort to support rapid, fair and equitable access to vaccines. It is aiming to mobilise two billion doses for the world by the end of the year. Australia made an up-front payment of $123 million to allow for the purchase of more than 25 million doses.